Q2 2026 saw 11% local currency growth, strong margins, and a robust net profit, aided by a $3M U.S. tariff refund. Core product segments outperformed, while Patient Care lagged in Sweden and France. Guidance narrowed to 5–7% growth, with 22% EBITDA margin maintained.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.